7/12/22, 6:06 PM
`
`Penn Medicine Immunotherapy Pioneer Carl June, MD, Awarded 2015 Paul Ehrlich and Ludwig Darmstaedter Prize | Penn Today
`
`Penn Medicine Immunotherapy Pioneer Carl June, MD,
`Awarded 2015 Paul Ehrlich and Ludwig Darmstaedter Prize
`U niversity of Pennsylvania cancer and HIV expert Carl June, MD, has been named one of two
`
`recipients of the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize for his outstanding work in
`cancer immunotherapy. Since 1952, the Paul Ehrlich and Ludwig Darmstaedter Prize has been
`awarded to scientists who have made great advancements in the fields in which Paul Ehrlich
`worked, in particular immunology, cancer research, microbiology, and chemotherapy. The prize is presented
`each year on March 14, the anniversary of Paul Erhlich’s birthday, in Frankfurt, Germany.
`
`June is the Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory
`Medicine in the Perelman School of Medicine at the University of Pennsylvania and director of Translational
`Research in Penn’s Abramson Cancer Center.
`
`He is widely recognized as leader of the team responsible for the first successful and sustained
`demonstration of the use of CAR T cell therapy, an investigational approach in which a patient’s cells are
`removed through an apheresis process similar to dialysis and modified in Penn's cell and vaccine production
`facility. Scientists there reprogram the patients’ T cells through a gene modification technique using a viral
`vector that trains them to recognize specific types of cancer cells. The modified cells – known as chimeric
`antigen receptor (CAR) T cells – are then infused back into the patient's body, where they multiply, hunt
`and attack tumor cells.
`
`The latest results of clinical trials of more than 125 patients showed a response rate of 90 percent among
`pediatric and adult acute lymphoblastic leukemia patients. Among patients with chronic lymphocytic
`leukemia, the earliest group the research team began clinical trials with, in 2010, about 50 percent of
`patients respond to the therapy, and remissions among some of the first patients treated with the approach
`now exceed four and a half years. Early results in studies of patients with lymphoma and myeloma are also
`promising, and clinical trials are now underway to test this approach in patients with solid tumors.
`
`Click here (http://www.uphs.upenn.edu/news/News_Releases/2015/03/june/) to view the full release.
`
`Writer
`
`https://penntoday.upenn.edu/news/penn-medicine-immunotherapy-pioneer-carl-june-md-awarded-2015-paul-ehrlich-and-ludwig-darmstaed
`
`1/2
`
`UPenn Ex. 2022
`Miltenyi v. UPenn
`IPR2022-00855
`
`C R E D I T S
`Holly Auer
`DAT E
`March 11, 2015
`

`

`7/12/22, 6:06 PM
`
`Penn Medicine Immunotherapy Pioneer Carl June, MD, Awarded 2015 Paul Ehrlich and Ludwig Darmstaedter Prize | Penn Today
`
`https://penntoday.upenn.edu/news/penn-medicine-immunotherapy-pioneer-carl-june-md-awarded-2015-paul-ehrlich-and-ludwig-darmstaed
`
`2/2
`
`UPenn Ex. 2022
`Miltenyi v. UPenn
`IPR2022-00855
`
`S U B TO P I C S
`Innovation
`S C H O O L S
`Perelman School of Medicine
`